BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Iwanami S, Ejima K, Kim KS, Noshita K, Fujita Y, Miyazaki T, Kohno S, Miyazaki Y, Morimoto S, Nakaoka S, Koizumi Y, Asai Y, Aihara K, Watashi K, Thompson RN, Shibuya K, Fujiu K, Perelson AS, Iwami S, Wakita T. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med 2021;18:e1003660. [PMID: 34228712 DOI: 10.1371/journal.pmed.1003660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Tatematsu D, Akao M, Park H, Iwami S, Ejima K, Iwanami S. Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors. J Theor Biol 2023;561:111403. [PMID: 36586664 DOI: 10.1016/j.jtbi.2022.111403] [Reference Citation Analysis]
2 Li Y, Niu L. Identification of the effects of COVID-19 on patients with pulmonary fibrosis and lung cancer: a bioinformatics analysis and literature review. Sci Rep 2022;12:16040. [PMID: 36163484 DOI: 10.1038/s41598-022-20040-x] [Reference Citation Analysis]
3 Jeong YD, Ejima K, Kim KS, Joohyeon W, Iwanami S, Fujita Y, Jung IH, Aihara K, Shibuya K, Iwami S, Bento AI, Ajelli M. Designing isolation guidelines for COVID-19 patients with rapid antigen tests. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-32663-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Ejima K, Kim KS, Bento AI, Iwanami S, Fujita Y, Aihara K, Shibuya K, Iwami S. Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study. BMC Infect Dis 2022;22:656. [PMID: 35902832 DOI: 10.1186/s12879-022-07646-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Kaplan HG, Wang K, Reeves KM, Scanlan JM, Nunn CC, Kieper DA, Mark JL, Lee I, Liu R, Jin R, Bolton MJ, Goldman JD. Reszinate—A Phase 1/2 Randomized Clinical Trial of Zinc and Resveratrol Utilizing Home Patient-Obtained Nasal and Saliva Viral Sampling. Front Drug Discov 2022;2. [DOI: 10.3389/fddsv.2022.910124] [Reference Citation Analysis]
6 Watson JA, Kissler SM, Day NPJ, Grad YH, White NJ. Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. Antimicrob Agents Chemother 2022;:e0019222. [PMID: 35736134 DOI: 10.1128/aac.00192-22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M. Stem cell therapy for COVID-19 pneumonia. Mol Biomed 2022;3:6. [PMID: 35174448 DOI: 10.1186/s43556-021-00067-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jeong YD, Ejima K, Kim KS, Joohyeon W, Iwanami S, Fujita Y, Jung IH, Shibuya K, Iwami S, Bento AI, Ajelli M. Designing isolation guidelines for COVID-19 patients utilizing rapid antigen tests: a simulation study using viral dynamics models.. [DOI: 10.1101/2022.01.24.22269769] [Reference Citation Analysis]
9 Fatehi F, Bingham RJ, Stockley PG, Twarock R. An age-structured model of hepatitis B viral infection highlights the potential of different therapeutic strategies. Sci Rep 2022;12:1252. [PMID: 35075156 DOI: 10.1038/s41598-021-04022-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Rossignol J. Rethinking methods used to evaluate effectiveness of therapeutics for COVID-19 and other viral respiratory illnesses. Future Virology. [DOI: 10.2217/fvl-2021-0209] [Reference Citation Analysis]
11 Jeong YD, Ejima K, Kim KS, Iwanami S, Iwami S, Aihara K. Safely return to schools and offices: early and frequent screening with high sensitivity antigen tests effectively identifies COVID-19 patients.. [DOI: 10.1101/2021.10.08.21264782] [Reference Citation Analysis]
12 Zarnitsyna VI, Gianlupi JF, Hagar A, Sego TJ, Glazier JA. Advancing therapies for viral infections using mechanistic computational models of the dynamic interplay between the virus and host immune response. Curr Opin Virol 2021;50:103-9. [PMID: 34450519 DOI: 10.1016/j.coviro.2021.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Fatehi F, Bingham RJ, Dykeman EC, Stockley PG, Twarock R. Comparing antiviral strategies against COVID-19 via multiscale within-host modelling. R Soc Open Sci 2021;8:210082. [PMID: 34430042 DOI: 10.1098/rsos.210082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
14 Vaidya NK, Bloomquist A, Perelson AS. Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets. Viruses 2021;13:1635. [PMID: 34452499 DOI: 10.3390/v13081635] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
15 Kim KS, Iwanami S, Oda T, Fujita Y, Kuba K, Miyazaki T, Ejima K, Iwami S. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. Life Sci Alliance 2021;4:e202101049. [PMID: 34344719 DOI: 10.26508/lsa.202101049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Watson JA, Kissler S, Day NP, Grad Y, White NJ. Characterising SARS-CoV-2 viral clearance kinetics to improve the design of antiviral pharmacometric studies.. [DOI: 10.1101/2021.01.06.21249368] [Reference Citation Analysis]
17 Akao M, Woo J, Iwami S, Iwanami S. Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. Translational and Regulatory Sciences 2021;3:85-88. [DOI: 10.33611/trs.2021-025] [Reference Citation Analysis]